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An association between lead poisoning and
renal disease in humans has been recognized
for more than a century (Wedeen et al. 1975).
Numerous epidemiologic studies, mortality
studies, and experimental studies in animals
have reported lead nephrotoxicity at high lev-
els of exposure; however, studies on the action
of lead on renal function at lower levels of
chronic exposure have produced a mixed pat-
tern of ﬁndings. Most of the studies found no
signiﬁcant association between low-level lead
exposure and renal dysfunction. To date, only
a few cross-sectional studies (Payton et al.
1994; Staessen et al. 1990, 1992) and one
longitudinal study (Kim et al. 1996) have
reported a signiﬁcant association between ele-
vated blood lead levels and reduced renal
function measured by serum creatinine (SCr)
or creatinine clearance in members of the
general population. In addition, a recent ran-
domized trial among individuals with elevated
environmental lead exposure demonstrating
improved creatinine clearance in those receiv-
ing chelation therapy provides evidence of
lead’s effect on the kidney (and its potential
reversibility) at community levels of exposure
(Lin et al. 2003).
Blood lead, which mostly reﬂects relatively
recent exposure, is an inadequate measure of
total body burden of lead, which may explain
why most of the previous observational studies
failed to ﬁnd a signiﬁcant association between
low-level lead exposure and renal function
impairment. Compared with concurrent blood
lead, bone lead, which comprises > 95% of
adult body lead burden and has a biologic half-
life ranging from years to decades, is a better
biologic marker for studying chronic toxicity
of accumulated exposure and lead burden
(Gonzalez-Cossio et al. 1997; Hu et al. 1996;
Korrick et al. 1999). In addition, bone lead
also serves as an endogenous source of lead
exposure for individuals with increased bone
turnover (Silbergeld 1991; Silbergeld et al.
1988). Therefore, bone lead may be a risk fac-
tor for impaired renal function either by serv-
ing as either a dosimeter of cumulative
exposure of the kidney to lead or a measure of
the major endogenous source of blood lead
that, in turn, may affect the kidney.
Given that an increase in bone resorption
is a characteristic of aging in both men and
women, aging-associated release of bone lead
into the circulation is a potentially important
source of soft-tissue lead exposure and toxic-
ity. Another factor associated with aging that
may increase the nephrotoxicity of lead is dia-
betes. The more prevalent form, type 2 dia-
betes, affects approximately 10% or more of
the general population (with substantially
higher rates at ≥ 55 years of age) (Ford 2001)
and is well known as an independent predic-
tor of accelerated decline in kidney function.
A third factor associated with aging that may
also increase the nephrotoxicity of lead is
hypertension.
In the present study, we used data from a
cohort of middle-age and elderly men who had
no previous known heavy lead exposure to
examine the effects of low-level bone and
blood lead levels on renal function. We also
examined the potential modifying effect of dia-
betes and hypertension on these relationships.
Materials and Methods
Study population. Study participants were
from the Normative Aging Study (NAS), a
longitudinal study of aging established by the
Veterans Administration in 1961 (Bell et al.
1972). The study cohort initially consisted of
2,280 men from the Greater Boston area who
were 21–80 years of age on enrollment. All
participants were free of known chronic medi-
cal conditions at enrollment; men with any
history of cancer, asthma, sinusitis, bronchi-
tis, diabetes, gout, or peptic ulcer were
excluded, as were those with a systolic blood
pressure of > 140 mmHg or a diastolic blood
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In this prospective study, we examined changes in renal function during 6 years of follow-up in
relation to baseline lead levels, diabetes, and hypertension among 448 middle-age and elderly
men, a subsample of the Normative Aging Study. Lead levels were generally low at baseline, with
mean blood lead, patella lead, and tibia lead values of 6.5 µg/dL, 32.4 µg/g, and 21.5 µg/g, respec-
tively. Six percent and 26% of subjects had diabetes and hypertension at baseline, respectively. In
multivariate-adjusted regression analyses, longitudinal increases in serum creatinine (SCr) were
associated with higher baseline lead levels but these associations were not statistically signiﬁcant.
However, we observed signiﬁcant interactions of blood lead and tibia lead with diabetes in pre-
dicting annual change in SCr. For example, increasing the tibia lead level from the midpoints of
the lowest to the highest quartiles (9–34 µg/g) was associated with an increase in the rate of rise in
SCr that was 17.6-fold greater in diabetics than in nondiabetics (1.08 mg/dL/10 years vs.
0.062 mg/dL/10 years; p < 0.01). We also observed signiﬁcant interactions of blood lead and tibia
lead with diabetes in relation to baseline SCr levels (tibia lead only) and follow-up SCr levels. A sig-
niﬁcant interaction of tibia lead with hypertensive status in predicting annual change in SCr was also
observed. We conclude that longitudinal decline of renal function among middle-age and elderly
individuals appears to depend on both long-term lead stores and circulating lead, with an effect that
is most pronounced among diabetics and hypertensives, subjects who likely represent particularly
susceptible groups. Key words: blood lead, bone lead, diabetes, hypertension, kidney function, serum
creatinine. Environ Health Perspect 112:1178–1182 (2004). doi:10.1289/ehp.7024 available via
http://dx.doi.org/ [Online 3 June 2004]pressure of > 90 mmHg. Since their enroll-
ment in 1961–1968, participants have been
reevaluated at 3- to 5-year intervals by a
detailed core examination including collection
of medical history information, routine physical
examinations, laboratory tests, and question-
naires. The mean of blood pressure measure-
ments in the left and right arms was used as
each participant’s systolic and diastolic blood
pressure. For the present study, “hypertensive”
was deﬁned as systolic blood pressure ≥ 160, or
diastolic blood pressure ≥ 95 mmHg, or a
physician’s diagnosis of hypertension with use
of antihypertensive medication. The diagnosis
of diabetes was based on clinical data from the
study core examination; specifically, partici-
pants were classiﬁed as diabetic if they a) used
oral hypoglycemic drugs, b) used insulin, or
c) reported a physician’s diagnosis of diabetes
whether or not they used diabetic drugs for
treatment.
A blood sample for lead analysis has been
collected at each NAS visit since July 1988.
Beginning in August 1991, NAS participants
were recruited for a substudy of K X-ray ﬂuo-
rescence (KXRF) bone lead measurement.
Subjects included in the present investigation
were those who participated in the KXRF
bone lead substudy with concurrent blood
lead, SCr, body mass index (BMI), alcohol
intake, and blood pressure data and a follow-
up measurement of SCr at least 4 years later.
All research performed in the present
study was approved by the Human Research
Committees of Brigham and Women’s
Hospital and the Department of Veterans
Affairs Outpatient Clinic.
Measurements. Bone lead was measured
in each subject’s midtibia shaft and patella
with a KXRF instrument (ABIOMED, Inc.,
Danvers, MA). The tibia and patella have
been targeted for bone lead research because
they consist mainly of cortical and trabecular
bone, respectively. A technical description and
the validity specifications of this instrument
have been published elsewhere (Burger et al.
1990; Hu et al. 1990). The KXRF instrument
provides an unbiased estimate of bone lead
levels (normalized for bone mineral content as
micrograms of lead per gram of bone mineral)
and an estimate of the uncertainty associated
with each measurement.
Whole-blood samples were obtained and
analyzed for lead by graphite furnace atomic
absorption with Zeeman background correction
(ESA Laboratories, Chelmsford, MA). Values
below the minimum detection limit of 1 µg/dL
were coded as 0. The instrument was calibrated
with National Institute of Standards and
Technology Standard Reference Material
(NIST SRM 955a, lead in blood) after every
20 samples. Ten percent of samples were run in
duplicate; at least 10% of the samples were con-
trols, and 10% were blanks. In tests on reference
samples from the Centers for Disease Control
and Prevention (Atlanta, GA), precision [coefﬁ-
cient of variation (CV)] ranged from 8% for
concentrations 10–30 µg/dL to 1% for higher
concentrations. Compared with an NIST target
of 5.7 µg/dL, 24 measurements by this method
gave a mean ± SD of 5.3 ± 1.23 µg/dL.
SCr concentration was determined by
a computerized automatic analyzer [Techni-
con SAM models (Technicon Corp., Tarry-
town, NY) from 1979 to 1993; Boehringer
Mannheim/Hitachi 747 analyzer (Boehringer-
Mannheim Corp, Indianapolis, IN) from 1993
and on] at each examination. The analyzer
measures creatinine based on the Jaffe proce-
dure (Jaffe 1886) and demonstrated excellent
reproducibility. This method of analysis has
intra-assay CVs of 1.3% at 1.2 mg/dL and
interassay CVs of 3.3% at 1.1 mg/dL.
Statistical methods. We used chi-square
analysis and Student’s t-test to compare par-
ticipants included in the analysis with eligible
nonparticipants. Because many of the vari-
ables had skewed distributions, we used the
nonparametric Wilcoxon signed-rank test for
continuous variables to compare their distrib-
utions between baseline and follow-up visit.
The main outcome of interest, annual change
in SCr (milligrams per deciliter per year) was
deﬁned as (follow-up SCr – baseline SCr)/years
of follow-up.
We used multiple linear regression analy-
ses to determine the associations between base-
line lead biomarkers (blood lead, patella lead,
and tibia lead) and annual change in SCr.
Because lead levels in blood and bone were
skewed toward the upper end, we used lead
biomarkers in the natural log scale to improve
stability over the whole range of lead levels.
The following variables at baseline were con-
sidered for possible inclusion in the models:
age, BMI, baseline SCr, diabetic status, hyper-
tensive status, smoking history [smoking status
(ever/never) and cumulative smoking in pack
years], alcohol consumption, and use of anal-
gesic medication and diuretic medication.
Alcohol consumption was analyzed both as a
continuous variable (grams per day) and as a
categorical variable: nondrinkers, light to
moderate drinkers (< 20 g/day), and heavy
drinkers (≥ 20 g/day).
To examine the modifying effect of dia-
betes on the nephrotoxicity of lead, we con-
structed models of the hypothesized interaction
of lead with diabetes as follows: Annual change
in SCr = intercept + β1(ID1) + β2(ID0 × mean-
centered lead) + β3 (ID1 × mean-centered lead)
+ (other covariates), where ID0 = 1 if nondiabetes
(reference group), 0 otherwise; ID1 = 1 if dia-
betes, 0 otherwise. We used this model to get
the slopes for the two groups and their statistical
signiﬁcance. We constructed a second multiple
regression model containing all main effects and
a two-way interaction between diabetic status
and natural-log–transformed baseline lead bio-
markers. The model is expressed as annual
change in SCr = intercept + β1(ID1) + β2(mean-
centered lead) + β3 (ID1 × mean-centered lead)
+ (other covariates), where ID1 = 1 if diabetes, 0
otherwise. The second model was to do the
statistical test of the interaction. If β3 differs
signiﬁcantly from zero, then diabetes is a sig-
niﬁcant effect modiﬁer. The inclusion of spe-
cific covariates in the final multiple linear
regression models was based on statistical and
biologic considerations. To minimize the pos-
sibility of reverse causation, we repeated the
analyses of annual change in SCr after exclud-
ing subjects with a high SCr at baseline, as
deﬁned by a value > 1.5 mg/dL. In addition,
we examined the cross-sectional associations of
baseline lead biomarkers with SCr measured at
baseline and follow-up visits. The same set of
confounders was considered for possible inclu-
sion in the cross-sectional analyses of SCr.
We used the same approach to examine
the modifying effect of hypertension on
the nephrotoxicity of lead. Analyses were
conducted using the Statistical Analysis
System (Unix SAS version 8.2; SAS Institute,
Cary, NC).
Results
An initial group of 707 NAS subjects who
participated in the KXRF substudy between
1991 and 1995 and who had complete data
on lead biomarkers, SCr, BMI, alcohol intake,
medication use history, and diagnoses and
blood pressure measurements were identiﬁed
as eligible study subjects at baseline. Among
them, 448 subjects had a follow-up measure-
ment of SCr at, on average, 6 years later
(range, 4–8). Selected characteristics of the
448 subjects at baseline and at follow-up are
shown in Table 1. No signiﬁcant differences
were found with respect to the distributions
of age, BMI, alcohol consumption, smoking
status, diabetic status, hypertensive status,
baseline SCr, and blood and bone lead levels
among eligible nonparticipants and partici-
pants at baseline. At baseline, 8% were current
smokers, 6% were classiﬁed as diabetic, 26%
were classified as hypertensive, 7% reported
using diuretic medication, and 78% reported
using analgesic medication. Only 5% of the
study subjects had reduced renal function
(SCr > 1.5 mg/dL) at baseline. Subjects with
diabetes at baseline had slightly higher bone
lead levels and lower blood lead levels than
those who were free of diabetes. Furthermore,
subjects with diabetes had greater increase in
SCr over time compared with those free of
diabetes at baseline (p = 0.03 from Wilcoxon
rank-sum test).
The nonparametric Wilcoxon signed-rank
test showed that the mean follow-up SCr
(1.06 mg/dL) was signiﬁcantly lower than the
mean baseline SCr (1.25 mg/dL), and blood
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this population (p < 0.05).
Associations of baseline and follow-up
SCr with blood and bone lead levels. Both
bone lead measures, but not blood lead, were
consistently and positively associated with
baseline SCr in cross-sectional analyses, but
these associations were not statistically signiﬁ-
cant (Table 2). However, a signiﬁcant inter-
action between diabetes and baseline tibia lead
level regressed on baseline SCr was observed
after adjusting for potential confounders
(Table 3). Specifically, the positive cross-
sectional association of tibia lead level with
SCr was substantially stronger and statistically
significant among diabetics compared with
nondiabetics. Similar effect modification by
diabetes was found with respect to the associa-
tion of baseline patella lead with baseline SCr,
but the interaction was not significant
(Table 3). Exclusion of diuretic medication
users or participants with SCr > 1.5 mg/dL
did not materially change the observed associ-
ations between lead levels and baseline SCr.
No signiﬁcant interaction between hyperten-
sives and baseline lead levels regressed on
baseline SCr was observed (Table 3).
Similarly, both baseline tibia lead measure-
ment and follow-up blood lead levels were
consistently and positively associated with
follow-up SCr, but only the association of fol-
low-up blood lead with follow-up SCr was sta-
tistically signiﬁcant (Table 2). In analogy to the
cross-sectional analysis, a signiﬁcant interaction
between diabetes and tibia lead on follow-up
SCr was observed (Table 3). Results remained
unchanged after diuretic medication users at fol-
low-up were excluded. Exclusion of participants
with SCr > 1.5 mg/dL did not materially change
the observed associations between baseline bone
lead levels and follow-up SCr. However, the
association of follow-up blood lead with follow-
up SCr and the interaction of blood lead with
diabetes in determining follow-up SCr became
nonsigniﬁcant after we excluded participants
with baseline SCr > 1.5 mg/dL. A signiﬁcant
interaction between hypertensive status and fol-
low-up blood lead level regressed on follow-up
SCr was observed (Table 3). Speciﬁcally, the
positive cross-sectional association of blood lead
level with SCr was substantially stronger and
statistically significant among hypertensives
compared with normotensives.
Association of annual change in SCr with
blood and bone lead levels. All three lead meas-
ures were positively associated with
longitudinal increases in SCr, but none of
these associations was statistically significant
(Table 2). However, we observed significant
interactions of both blood and tibia lead with
diabetes in predicting annual change in SCr
after adjusting for baseline covariates (Table 3).
For example, increasing the tibia lead level
from the midpoints of the lowest to the highest
quartiles (9–34 µg/g) was associated with an
increase in the rate of rise of SCr that was
17.6-fold greater in diabetics than nondiabetics
(1.084 mg/dL over 10 years vs. 0.062 mg/dL
over 10 years). Similarly, increasing baseline
blood lead levels from the midpoints of the
lowest to the highest quartiles (3–11.25 µg/dL)
was associated with an increase in the rate of
rise of SCr that was 12.8-fold greater in dia-
betics than nondiabetics (1.01 µg /dL over
10 years vs. 0.08 µg /dL over 10 years)
(Figure 1). Exclusion of participants with
baseline SCr > 1.5 mg/dL did not materially
change the observed longitudinal associations
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Table 1. Characteristics of the 707 eligible subjects and the 448 NAS subjects at baseline (1991–1995) and at follow-up visit [mean ± SD or no. (%)].
Participants in this study
Baseline eligible subjects Baseline Follow-up
Characteristic Mean ± SDa Mean ± SDa No. Mean ± SDa
Tibia lead (µg/g) 21.9 ± 13.3 21.5 ± 13.5 247 23.8 ± 16.8*
Patella lead (µg/g) 32.0 ± 19.6 32.4 ± 20.5 258 31.1 ± 23.5*
Blood lead (µg/dL) 6.2 ± 4.1 6.5 ± 4.2 427 4.5 ± 2.5*
Age (years) 66.9 ± 7.2 66.0 ± 6.6 448 72.0 ± 6.5*
SCr (mg/dL) 1.2 ± 0.2 1.25 ± 0.2 448 1.1 ± 0.4*
Body mass index (kg/m2) 27.8 ± 3.8 27.8 ± 3.7 399 28.2 ± 3.9*
Alcohol consumption (g/day) 13.1 ± 17.9 13.4 ± 17.9 386 13.5 ± 20.2
Serum albumin (g/dL) 4.7 ± 0.3 4.7 ± 0.3 448 4.4 ± 0.3*
Pack-years of smokingb 22.3 ± 25.6 19.5 ± 23.6 437 19.7 ± 24.2*
Energy-adjusted protein intake (g/day) 82.2 ± 15.7 82.4 ± 16.4 386 80.5 ± 15.4*
Follow-up time (year) ND ND 448 6.0 ± 0.5
Changes in SCr (mg/dL-year) ND ND 448 –0.03 ± 0.1
Smoking status 443
Never 210 (29.7)c 145 (32.4)c 145 (32.7)c
Current 61 (8.6) 36 (8.0) 26 (5.9)
Former 436 (61.7) 267 (59.6) 272 (61.4)
Hypertensivesd 198 (28.0) 115 (25.7) 448 126 (28.1)
Clinical diagnosed diabetes mellitus 54 (7.6) 26 (5.8) 448 52 (11.6)
Use of diuretics (yes) 62 (8.8) 33 (7.4) 448 63 (14.1)
Use of aspirin or pain medication (yes) 540 (76.4) 349 (77.9) 448 355 (79.2)
SCr > 1.5 mg/dL (yes) 41 (5.8) 24 (5.4) 448 23 (5.1)
Alcohol consumption 386
None 184 (26.1) 108 (24.1) 94 (24.4)
0–20 (g/day) 371 (52.5) 243 (54.2) 215 (55.7)
≥ 20 (g/day) 152 (21.5) 97 (21.7) 77 (20.0)
ND, no data.
aValues are mean ± SD except where indicated. bNine eligible subjects and six baseline subjects were missing pack-year smoking data. cNo. (%). dHypertensive was deﬁned as systolic
blood pressure ≥ 160, or diastolic blood pressure ≥ 95 mmHg, or a physician’s diagnosis of hypertension with use of antihypertensive medication. *Values at baseline and follow-up were
signiﬁcantly different (p < 0.05 by Wilcoxon signed-rank test).
Table 2. Multiple regression analysis of SCr on blood or bone lead in the NAS [β (SE)].
Model of Model of Model of
Variable baseline SCra follow-up SCrb changes in SCrc
Loge(baseline blood lead) –0.023 (0.019) 0.009 (0.005)
Loge(follow-up blood lead) 0.149 (0.055)*
Loge(baseline patella lead) 0.011 (0.017) –0.006 (0.043) 0.001 (0.004)
Loge(baseline tibia lead) 0.017 (0.020) 0.065 (0.049) 0.007 (0.005)
aAdjusted for age, age squared, BMI, alcohol intake (< 20, ≥ 20 g/day vs. nondrinkers), ever smoking, pain medication,
hypertension, and diabetes. bAdjusted for follow-up variables of age, BMI, alcohol intake (< 20, ≥ 20 g/day vs. non-
drinkers), ever smoking, pain medication, hypertension, and diabetes. cAdjusted for baseline variables of SCr, SCr
squared, age, BMI, alcohol intake (< 20, ≥ 20 g/day vs. nondrinkers), ever smoking, pain medication, hypertension, and
diabetes. *p < 0.05 for the β-coefﬁcient.between lead levels and change in SCr. The
direction of the observed longitudinal associa-
tions between lead levels and SCr remained
the same after we excluded diuretic medica-
tion users at baseline, but the interaction
between blood lead and tibia lead and dia-
betes became nonsigniﬁcant. Similar ﬁndings
were observed after exclusion of hypertensive
subjects at baseline.
We also observed signiﬁcant interactions of
tibia lead with hypertension in predicting
annual change in SCr after adjusting for base-
line covariates (Table 3). Increasing the tibia
lead level from the midpoints of the lowest to
the highest quartiles (9–34 µg/g) was associated
with an increase in the rate of rise of SCr that
was > 50-fold greater in hypertensives than in
normotensives (0.31 mg/dL over 10 years vs.
0.005 mg/dL over 10 years) (Figure 1).
There was no interaction of alcohol con-
sumption or smoking with lead biomarkers in
determining annual change in SCr. Assessment
for a potential interaction between race and
lead exposure in determining annual change in
SCr was limited by small numbers (n = 12,
2.7% black participants). Excluding this group
from the analysis did not change the observed
associations
Discussion
In this study, signiﬁcant associations of bone
lead (particularly tibia bone) with prospective
follow-up measures and annual change in
SCr were observed among subjects with dia-
betes. We also observed significant positive
associations of blood lead with prospective
annual change in SCr among diabetics and
cross-sectional increases in SCr (at the follow-
up exam) among nondiabetics. Associations of
higher blood lead with poorer renal function
have been described elsewhere among non-
occupationally exposed populations. A positive
correlation between SCr concentration and
blood lead levels was found in a survey of men
in the British civil service (Staessen et al.
1990). In general population studies in
Belgium and in the United States (the NAS
cohort in Boston), creatinine clearance was
inversely associated with blood lead levels
(Payton et al. 1994; Staessen et al. 1992).
Furthermore, in a recent longitudinal analysis
of the NAS cohort, there was a positive asso-
ciation between low lead levels and SCr (Kim
et al. 1996).
The analysis of lead, hypertension, and
SCr indicates that both the association
between follow-up blood lead with follow-up
measures of SCr and the association between
tibia lead and prospective annual change in
SCr were signiﬁcantly modiﬁed by hyperten-
sive status, with hypertensive subjects having
stronger and more signiﬁcant associations. A
recent analysis from the Third National
Health and Nutrition Examination Survey
(NHANES III) also showed a signiﬁcant asso-
ciation of higher blood lead levels with
chronic kidney disease and elevated SCr
among hypertensives. Relationships among
lead exposure, impaired renal function, and
hypertension are complex: Lead exposure has
been associated with an increased risk of
hypertension, and essential hypertension, in
turn, is a well-established risk factor for kidney
disease. Whether lead affects blood pressure
indirectly through alterations in kidney func-
tion or via more direct effects on the vascula-
ture or neurologic blood pressure control is
unknown. The interaction of hypertension,
lead, and kidney function merits further inves-
tigation in a prospective cohort.
Studies of lead body burden estimated by
EDTA mobilization tests have revealed a cor-
relation of high body lead burden with
declines in renal function (Batuman et al.
1983; Lin and Huang 1994; Lin et al. 2001).
There have been a few studies of the associa-
tion between body burden in the form of bone
lead and renal function, but the results have
been inconclusive. Furthermore, most prior
studies have assessed occupationally exposed
populations. For example, no adverse effects of
bone lead on renal function were found in
Swedish smelter works (Gerhardsson et al.
1992), whereas a positive association of tibia
lead with glomerular hyperfiltration was
reported in Belgian lead workers, suggesting
the potential for a paradoxical protective effect
of bone lead on renal function (Roels et al.
1994). The present study is among the ﬁrst to
assess the relation of bone lead levels from a
general population sample with measures of
renal function. Our findings support the
hypothesis that long-term low-level lead accu-
mulation (estimated by tibia bone lead) is
associated with an increased risk of declining
renal function particularly among diabetics or
hypertensives, populations already at risk for
impaired renal function.
However, there are several limitations to
our findings. In the absence of diabetes or
hypertension, we did not see statistically signif-
icant associations of bone lead levels with
either cross-sectional or longitudinal measures
of renal function. Our study population was
not occupationally exposed and therefore had
relatively low lead levels, whereas the clearest
associations of lead with decrements in renal
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Figure 1. The modifying effect of diabetes and
hypertension on the 10-year change in SCr associ-
ated with increasing tibia and blood lead levels from
the midpoints of their lowest to their highest quar-
tiles (25 µg/g and 8 µg/dL increases, respectively).
Error bars indicate 95% conﬁdence intervals.
Tibia lead (µg/g) Blood lead (µg/dL)
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Table 3. Multiple regression analysis of SCr on blood or bone lead in the NAS stratiﬁed by baseline diabetic
status [β (SE)].
Variable, diabetic or Model of Model of Model of
hypertensive status baseline SCra follow-up SCrb changes in SCrc
Loge (baseline blood lead)
Diabetic (n = 26) –0.054 (0.089) 0.076 (0.023)*,**
Nondiabetic (n = 422) –0.022 (0.019) 0.006 (0.005)
Hypertensive (n = 115) –0.009 (0.039) 0.008 (0.010)
Normotensive (n = 333) –0.027 (0.021) 0.009 (0.006)
Loge (follow-up blood lead)
Diabetic (n = 24) 0.223 (0.183)
Nondiabetic (n = 403) 0.142 (0.058)*
Hypertensive (n = 108) 0.352 (0.097)*,**
Normotensive (n = 319) 0.058 (0.065)
Loge (baseline patella lead)
Diabetic (n = 26) 0.056 (0.065) 0.007 (0.107) 0.004 (0.017)
Nondiabetic (n = 422) 0.008 (0.017) –0.008 (0.047) 0.0004 (0.005)
Hypertensive (n = 115) 0.052 (0.034) –0.019 (0.075) 0.009 (0.009)
Normotensive (n = 333) –0.0003 (0.019) –0.0005 (0.051) –0.002 (0.005)
Loge (baseline tibia lead)
Diabetic (n = 26) 0.229 (0.102)*,** 0.699 (0.192)*,** 0.082 (0.027)*,**
Nondiabetic (n = 422) 0.011 (0.020) 0.029 (0.049) 0.005 (0.005)
Hypertensive (n = 115) 0.027 (0.037) 0.180 (0.097) 0.023 (0.010)*,**
Normotensive (n = 333) 0.013 (0.024) 0.030 (0.055) 0.0004 (0.006)
aAdjusted for age, age squared, BMI, alcohol intake (< 20, ≥ 20 g/day vs. nondrinkers), ever smoking, pain medication,
hypertension, and diabetes. bAdjusted for follow-up variables of age, BMI, alcohol intake (< 20, ≥ 20 g/day vs.nondrinkers),
ever smoking, pain medication, hypertension, and diabetes. cAdjusted for baseline variables of SCr, SCr squared, age, BMI,
alcohol intake (< 20, ≥ 20 g/day vs. nondrinkers), ever smoking, pain medication, hypertension, and diabetes. *p < 0.05 for
the β-coefﬁcient. **p < 0.05 for the interaction between lead variable and diabetic or hypertensive status.Article | Tsaih et al.
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function have been demonstrated among heav-
ily exposed populations. Although SCr is a
widely used measure of renal function in clini-
cal medicine, it provides only a rough estimate
of glomerular function. Increases in SCr are
relatively insensitive to declining glomerular ﬁl-
tration and are evident (i.e., > 1.5 mg/dL) only
when kidney function has been reduced by
about 50%. Therefore, low exposures and the
relative insensitivity of our outcome measure
may have limited our ability to detect more
modest lead effects. Furthermore, we observed
an unexpected overall decline in SCr over time
in this population. SCr is a function of muscle
mass and diet, as well as the glomerular ﬁltra-
tion rate. A possible explanation for the lower
follow-up SCr we observed includes decreased
creatinine generation attributable to reduced
muscle mass as a result of aging or reduced
meat intake. However, SCr level was not asso-
ciated with total energy-adjusted protein intake
either at baseline or at the follow-up in the pre-
sent study. Therefore, protein intake did not
appear to confound the relation of SCr with
lead exposure. Baseline and follow-up SCr
were measured using the same technique and
established standards and calibration methods,
making measurement drift an unlikely explana-
tion for lower follow-up values.
In addition, our diagnostic criteria for dia-
betes may misclassify individuals. However,
this type of misclassiﬁcation is likely to be non-
differential with respect to the null hypothesis
of no association, because nondiabetic individ-
uals who had high or low lead exposure (and
high or low SCr) would be equally likely to be
misclassified as diabetic. The same is true
regarding diabetic individuals being misclassi-
fied as nondiabetics. Such a nondifferential
misclassiﬁcation will tend to drive the overall
effect toward a null ﬁnding (attenuated para-
meter estimates) but will not drive a true null
ﬁnding toward an effect.
Our ﬁndings do not necessarily exclude the
alternative hypothesis that elevated bone (or
blood) lead levels were a result of impaired
renal function. However, studies have shown
that body lead burden was not elevated among
patients with renal insufficiency or chronic
renal failure if they did not have a history of
childhood plumbism or high lead exposure
(Batuman et al. 1983; Lin and Huang 1994;
Sanchez-Fructuoso et al. 1996). For the most
part, participants’ SCr levels were well within
the normal range throughout the follow-up
period of the study, and excluding individuals
with elevated SCr at baseline did not materially
alter our ﬁndings. These observations in com-
bination with the prospective study design sup-
port the conclusion that the direction of the
association is lead dose resulting in renal dys-
function. Hypertensive status has been shown
to be associated with increases in SCr (Staessen
et al. 1990, 1992) and with bone lead levels in
the NAS (Hu et al. 1996). However, inclusion
or exclusion of hypertension in the models
did not make substantial differences in the
observed associations except as noted in the
interaction analyses.
Although tibia lead was clearly associated
with longitudinal decrements in renal function
among the study’s diabetics, patella lead was
not. Differential sensitivity of tibia versus
patella lead in predicting health outcomes has
been observed previously (Payton et al. 1998)
and may be a consequence of presumed differ-
ent lead toxicokinetics in cortical (tibia) and
trabecular (patella) bone. Previous research
demonstrated overall declines in patella lead
but stable tibia lead levels in this population
(Kim et al. 1997) during 3 years of follow-up,
which implies that patella lead may not reﬂect
past cumulative exposures as accurately as tibia
lead levels. In addition, the null finding for
patella lead may be due to higher uncertain-
ties, that is, greater measurement error, in
patella lead measurements than in tibia lead
measurements (Hu et al. 1991).
Several factors related to blood and bone
lead levels, including age, cigarette smoking, and
alcohol consumption are potential confounders
of the lead–SCr relationship. However, SCr
level was not associated with age, cigarette
smoking, or alcohol use in the present study.
Therefore, these factors did not appear to con-
found the relation of SCr with lead exposure.
In summary, our findings suggest that
both blood lead and cumulative lead burden,
reflected by tibia (cortical) bone lead levels,
are predictors of prospective increases in SCr
among middle-age and elderly men with dia-
betes or hypertension. To our knowledge, no
previous studies have reported an analysis of
the potential for diabetes to modify the rela-
tionship between lead exposure and renal
function. Such an interaction may be related
to the joint effect of the glomerular pathology
associated with diabetes and the tubular atro-
phy and interstitial nephritis/fibrosis associ-
ated with lead. Given how common a history
of environmental or occupational lead expo-
sure is among adults and the high prevalence
(and growing incidence) of type 2 diabetes in
the general population, an interaction as sug-
gested in this study would be of significant
public health importance if confirmed.
Additional research in this area—both epi-
demiologic and experimental involving, for
example, the diabetic rat—would be helpful.
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